# AIM ImmunoTech Inc.: financial statements, quarterly

AIM · NYSE · CIK 946644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aim.md) · [Financials](/companies/aim/financials.md) · [Filings](/companies/aim/filings.md) · [Insiders](/companies/aim/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aim/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001493152-24-045971.md) | [0.1 d](/filings/0001641172-25-000847.md) | [0.0](/filings/0001641172-25-011033.md) | [0.1](/filings/0001493152-25-011986.md) | [0.0](/filings/0001493152-25-023894.md) | [0.0 d](/filings/0001493152-26-013301.md) | [0.0](/filings/0001493152-26-023750.md) | [0.0](/filings/0001493152-26-036609.md) | [0.0](/filings/0001493152-25-023894.md) | [0.0 d](/filings/0001493152-26-013301.md) | [0.0](/filings/0001493152-26-023750.md) | [0.0](/filings/0001493152-26-036609.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [2.7](/filings/0001493152-24-045971.md) | [3.2 d](/filings/0001641172-25-000847.md) | [2.0](/filings/0001641172-25-011033.md) | [1.1](/filings/0001493152-25-011986.md) | [1.4](/filings/0001493152-25-023894.md) | [1.7 d](/filings/0001493152-26-013301.md) | [1.1](/filings/0001493152-26-023750.md) | [1.2](/filings/0001493152-26-036609.md) | [0.6](/filings/0001493152-25-023894.md) | [1.1 d](/filings/0001493152-26-013301.md) | [0.5](/filings/0001493152-26-023750.md) | [0.6](/filings/0001493152-26-036609.md) |
| Operating income | $m | [(8.2)](/filings/0001493152-24-045971.md) | [(14.0) d](/filings/0001641172-25-000847.md) | [(5.7)](/filings/0001641172-25-011033.md) | [(3.7)](/filings/0001493152-25-011986.md) | [(4.5)](/filings/0001493152-25-023894.md) | [(5.9) d](/filings/0001493152-26-013301.md) | [(3.6)](/filings/0001493152-26-023750.md) | [(2.6)](/filings/0001493152-26-036609.md) | [(2.4)](/filings/0001493152-25-023894.md) | [(3.0) d](/filings/0001493152-26-013301.md) | [(2.2)](/filings/0001493152-26-023750.md) | [(3.5)](/filings/0001493152-26-036609.md) |
| Interest expense | $m | not reported | not reported | [0.1](/filings/0001641172-25-011033.md) | [0.2](/filings/0001493152-25-011986.md) | [0.2](/filings/0001493152-25-023894.md) | [0.1 d](/filings/0001493152-26-013301.md) | [0.1](/filings/0001493152-26-023750.md) | [0.1](/filings/0001493152-26-036609.md) | [0.1](/filings/0001493152-25-023894.md) | [0.4 d](/filings/0001493152-26-013301.md) | [0.3](/filings/0001493152-26-023750.md) | [0.3](/filings/0001493152-26-036609.md) |
| Net income | $m | [(7.8)](/filings/0001493152-24-045971.md) | [(12.6) d](/filings/0001641172-25-000847.md) | [(5.8)](/filings/0001493152-25-023894.md) | [(1.8)](/filings/0001493152-25-023894.md) | [(3.7)](/filings/0001493152-25-023894.md) | [(6.0) d](/filings/0001493152-26-013301.md) | [(3.7)](/filings/0001493152-26-036609.md) | [(2.8)](/filings/0001493152-26-036609.md) | [(3.3)](/filings/0001493152-25-023894.md) | [(4.2) d](/filings/0001493152-26-013301.md) | [(3.0)](/filings/0001493152-26-036609.md) | [(3.8)](/filings/0001493152-26-036609.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001493152-24-045971.md) | not reported | [(0.12)](/filings/0001641172-25-011033.md) | [(3.00)](/filings/0001493152-25-011986.md) | [(6.00)](/filings/0001493152-25-023894.md) | not reported | [(0.05)](/filings/0001493152-26-023750.md) | [(3.68)](/filings/0001493152-26-036609.md) | [1.57](/filings/0001493152-25-023894.md) | not reported | [(0.69)](/filings/0001493152-26-023750.md) | [(0.43)](/filings/0001493152-26-036609.md) |
| Basic EPS | $ per share | [(0.16)](/filings/0001493152-24-045971.md) | not reported | [(0.12)](/filings/0001641172-25-011033.md) | [(3.00)](/filings/0001493152-25-011986.md) | [(6.00)](/filings/0001493152-25-023894.md) | not reported | [(0.05)](/filings/0001493152-26-023750.md) | [(3.68)](/filings/0001493152-26-036609.md) | [1.57](/filings/0001493152-25-023894.md) | not reported | [(0.69)](/filings/0001493152-26-023750.md) | [(0.43)](/filings/0001493152-26-036609.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | period not labelled (2024-12-11) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.4](/filings/0001641172-25-000847.md) | [3.3](/filings/0001493152-24-019917.md) | [3.6](/filings/0001493152-24-032355.md) | [0.9](/filings/0001493152-24-045971.md) | not reported | [1.7](/filings/0001493152-26-013301.md) | [0.9](/filings/0001641172-25-011033.md) | [0.5](/filings/0001493152-25-011986.md) | [2.3](/filings/0001493152-25-023894.md) | [3.0](/filings/0001493152-26-036609.md) | [5.8](/filings/0001493152-26-023750.md) | [9.9](/filings/0001493152-26-036609.md) |
| Current assets | $m | [14.6](/filings/0001641172-25-000847.md) | [11.3](/filings/0001493152-24-019917.md) | [10.4](/filings/0001493152-24-032355.md) | [7.6](/filings/0001493152-24-045971.md) | not reported | [4.2](/filings/0001493152-26-013301.md) | [2.6](/filings/0001641172-25-011033.md) | [1.0](/filings/0001493152-25-011986.md) | [2.6](/filings/0001493152-25-023894.md) | [3.3](/filings/0001493152-26-036609.md) | [6.2](/filings/0001493152-26-023750.md) | [10.4](/filings/0001493152-26-036609.md) |
| Total assets | $m | [19.4](/filings/0001641172-25-000847.md) | [16.2](/filings/0001493152-24-019917.md) | [15.7](/filings/0001493152-24-032355.md) | [13.6](/filings/0001493152-24-045971.md) | not reported | [8.6](/filings/0001493152-26-013301.md) | [6.2](/filings/0001641172-25-011033.md) | [4.1](/filings/0001493152-25-011986.md) | [5.5](/filings/0001493152-25-023894.md) | [5.8](/filings/0001493152-26-036609.md) | [8.6](/filings/0001493152-26-023750.md) | [12.7](/filings/0001493152-26-036609.md) |
| Current liabilities | $m | [8.7](/filings/0001641172-25-000847.md) | [9.9](/filings/0001493152-24-019917.md) | [8.8](/filings/0001493152-24-032355.md) | [10.1](/filings/0001493152-24-045971.md) | not reported | [9.5](/filings/0001493152-26-013301.md) | [9.8](/filings/0001641172-25-011033.md) | [10.4](/filings/0001493152-25-011986.md) | [4.0](/filings/0001493152-25-023894.md) | [6.2](/filings/0001493152-26-036609.md) | [6.1](/filings/0001493152-26-023750.md) | [4.9](/filings/0001493152-26-036609.md) |
| Total liabilities | $m | [9.1](/filings/0001641172-25-000847.md) | [11.4](/filings/0001493152-24-019917.md) | [9.6](/filings/0001493152-24-032355.md) | [10.7](/filings/0001493152-24-045971.md) | not reported | [9.9](/filings/0001493152-26-013301.md) | [10.1](/filings/0001641172-25-011033.md) | [10.7](/filings/0001493152-25-011986.md) | [11.6](/filings/0001493152-25-023894.md) | [15.6](/filings/0001493152-26-036609.md) | [6.5](/filings/0001493152-26-023750.md) | [5.0](/filings/0001493152-26-036609.md) |
| Long-term debt | $m | not reported | [1.0](/filings/0001493152-24-019917.md) | [0.3](/filings/0001493152-24-032355.md) | [0.1](/filings/0001493152-24-045971.md) | not reported | [2.8](/filings/0001493152-26-013301.md) | [2.4](/filings/0001641172-25-011033.md) | [2.7](/filings/0001493152-25-011986.md) | not reported | [0.9](/filings/0001493152-26-036609.md) | [0.2](/filings/0001493152-26-023750.md) | [3.6](/filings/0001493152-26-036609.md) |
| Current portion of debt | $m | not reported | [1.6](/filings/0001493152-24-019917.md) | [2.4](/filings/0001493152-24-032355.md) | [2.6](/filings/0001493152-24-045971.md) | not reported | [2.3](/filings/0001493152-26-013301.md) | [2.0](/filings/0001641172-25-011033.md) | [2.3](/filings/0001493152-25-011986.md) | [1.9](/filings/0001493152-25-023894.md) | [3.5](/filings/0001493152-26-036609.md) | [4.0](/filings/0001493152-26-023750.md) | [3.6](/filings/0001493152-26-036609.md) |
| Shareholders' equity | $m | [10.2](/filings/0001493152-26-013301.md) | [4.8](/filings/0001493152-25-023894.md) | [6.1](/filings/0001493152-25-023894.md) | [2.9](/filings/0001493152-25-023894.md) | [6.0](/filings/0001641172-25-011033.md) | [(1.3)](/filings/0001493152-26-036609.md) | [(3.9)](/filings/0001493152-26-036609.md) | [(6.5)](/filings/0001493152-26-036609.md) | [(6.1)](/filings/0001493152-25-023894.md) | [(9.8)](/filings/0001493152-26-036609.md) | [2.1](/filings/0001493152-26-036609.md) | [7.7](/filings/0001493152-26-036609.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,671) d](/filings/0001493152-24-045971.md) | [(9,758) d](/filings/0001641172-25-000847.md) | [(4,815)](/filings/0001641172-25-011033.md) | [(3,008) d](/filings/0001493152-25-011986.md) | [(3,110) d](/filings/0001493152-25-023894.md) | [(3,955) d](/filings/0001493152-26-013301.md) | [(2,361)](/filings/0001493152-26-023750.md) | [(1,531) d](/filings/0001493152-26-036609.md) | [(5,079) d](/filings/0001493152-25-023894.md) | [(1,986) d](/filings/0001493152-26-013301.md) | [(2,719)](/filings/0001493152-26-023750.md) | [(4,590) d](/filings/0001493152-26-036609.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-013301.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.1](/filings/0001493152-23-041294.md) | [48.4](/filings/0001493152-24-019917.md) | [48.4](/filings/0001493152-24-032355.md) | [48.6](/filings/0001493152-24-045971.md) | [49.5](/filings/0001641172-25-011033.md) | [0.5](/filings/0001493152-25-011986.md) | [0.6](/filings/0001493152-25-023894.md) | [0.7](/filings/0001493152-26-023750.md) | [0.8](/filings/0001493152-26-036609.md) | [2.1](/filings/0001493152-25-023894.md) | [4.4](/filings/0001493152-26-023750.md) | [17.1](/filings/0001493152-26-036609.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,442,139 at 2026-08-07, from the cover of the [10-Q filed 2026-08-07](/filings/0001493152-26-036609.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.